Hannah - you&me, neverending history 💜

Not sure focusing on charting for next week’s clinic is going to be enough to shake me out of peak delulu right now but it’s worth a shot. Last night, a dream come true 🥹 #RUNSEOKJIN_epTOUR

It’s mental health awareness week so I just wanted to remind people that what you see is not always what is going on behind the scenes. This photo was a selfie my husband took and posted on Facebook just before he came home and ended his life. Nobody at the party that night had

#Germline #genetictesting improves #overallsurvival (OS) in #patients w/ #pancreaticcancer 5yr OS in #patients w/ #germlinetesting 12% 5yr OS in #patients w/o #germlinetesting 1.8% Of those #patients w/ #germlinetesting Pathogenic Germline Variants (PGVs), 7 treated w/ #olaparib (#BRCA1/2), 1 treated w/ #pembrolizumab (#MSH6) OS for #patients w/ PGVs on #targetedtherapy was significantly improved vs #patients w/ PGVs who received standard-of-care therapy (HF, 0.09) c/w journals.lww.com/ctg/fulltext/2… @PedroUson et al. @ACG_CTG #Universal #germlinetesting in all #patients w/ #pancreaticcancer c/w ascopubs.org/doi/10.1200/JC… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention ascopubs.org/doi/abs/10.120… #ThomasOConnor et al. @JCOPO_ASCO @ASCO

>23% of #patients w/ #pancreatobiliary #ampullarycancer had PGVs in homologous recombination (HR) pathway genes alone (#BRCA1, #BRCA2, #PALB2, #ATM) w/ #germline #genetictesting "Our findings reinforce #clinicalguidelines supporting #germlinetesting in #ampullarycancer to inform both HR-directed therapies and #immunotherapy" One more reason for #universal #germlinetesting in all #patients w/ #cancer c/w ascopubs.org/doi/10.1200/PO… @EdEsplin et al. @JCOPO_ASCO ascopubs.org/doi/10.1200/JC… @VivekSubbiah @Dr_R_Kurzrock @JCO_ASCO @ASCO #access #reducedisparities #precisionmedicine #precisiontherapy #clinicaltrials #precisionprevention ascopubs.org/doi/full/10.12… #MaksymMisyura et al. @JCOPO_ASCO

Basser Fellow Minh Than, MD, PhD, presents research recently published in @ScienceMagazine w/ Bob Vonderheide, Director of @PennCancer, as co-author, shows precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. spr.ly/6018BBa8iC

A critical study for improving outcomes for #pancreaticcancer - we can’t 🎯 therapies and risk reduction efforts if we don’t test! Getting a pulse on our current practices is an essential step. 🌟 shining stars of GI cancers right here ⬇️

expansion to Mass General KST-6051

@MPishvaian @TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD At my institution all esophageal/gastric adenocarcinomas get reflexed for MMR, Claudin18, HER-2 and PD-L1 CPS 🩷

Music lovers and fan girls often list the shows they have attended in their bio. How might this translate for #ASCO meetings? What exciting and inspiring plenary presentations have you witnessed firsthand in the meeting hall? #TAILORx trial plenary presentation #LAURA #MATTERHORN And this year I will be there for the monumental occasion of a pancreas trial #RASolute #Letsgo

@MPishvaian @aprilchoi_md @TumorBoardTues @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD Now that we ESOPEC and MATTERHORN results, the treatment for locally advanced gastric/GEJ/esophageal adenoca has become much more streamlined. No more CROSS versus FLOT debates as much for adenoca. Siewart classification could still matter for surgical planning.

@aprilchoi_md @TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM @Senthilsurgonc @M_P_OLeary 😳😳😳 that needs more than a drumroll- wow!

@TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM @Senthilsurgonc @M_P_OLeary 17/21 #TumorBoardTuesday #GEJCancer #OncTwitter #MiniTweetorial 4 What about HER2 positive 🎀disease? MATTERHORN did not report on HER2 status… that said 🥁🥁 HER-FLOT (Ph2 1-arm): FLOT + Trastuzumab → pCR 21.4% PHERFLOT (Ph2 1-arm): D-FLOT + Trastuzumab → pCR 48.4%❗❗❗

#TumorBoardTuesday ⌛️1y ago we learned of a major📈in the cure for early stage gastric cancer 📢Join us Tuesday, 05-12-26 at 8PM ET as @SunnieSKim & @aprilchoi_md 🗣️updates to the MATTERHORN trial & Tx for early stage #gastriccancer RT and bring others into the discussion‼️

@SunnieSKim @MPishvaian @aprilchoi_md @TumorBoardTues @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM Which is why neoadjuvant carbo taxol xrt vs FLOT was not superior?! #TumorBoardTuesday

@HannahAlison20 @MPishvaian @aprilchoi_md @TumorBoardTues @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM pCR only assesses effect on primary tumor. What determines survival is the treatment's effect on micrometastatic disease

@TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM #TumorBoardTuesday #GEJCancer #OncTwitter Addition of durvalumab to FLOT did NOT impact completion of perioperative therapy Rates of surgery completion (86.9% vs 84.4%), R0 resection (91.5% vs 93.2%), and adjuvant treatment (48.3% vs 51.7%) were similar between the two groups

@MPishvaian @aprilchoi_md @TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM What is the reason for this? Do we know? Also not me coming off private because #TumorBoardTuesday I can’t resist learning about this topic!

@aprilchoi_md @TumorBoardTues @SunnieSKim @IntegrityCE @sundar_raghav @YJanjigianMD @KlempnerSam @FilippoPietran4 @sonbol_bassam @GIMedOnc @AnwaarSaeed3 @rutikamehtaMD @ReetuMukherjiMD @NEJM #TumorBoardTuesday Great outcomes - so not to take away anything, but just a reminder that surprisingly an increased pathCR alone has not been a predictor for an improved OS in other upperGI cancer trials

Daniel Lin, MD of @UW @UWMedicine presents: The Utility of Enhanced Screening for People with Inherited Risk of Developing Aggressive Prostate Cancer: Initial Results from the PATROL Study #bassersymposium

We need influential medical experts to be active here on X. We can help by providing good medical information and updates for patients and colleagues. We can network. We can counter misinformation. Clarify complex questions. Share accomplishments and publications. And more. I learn every day. Although X has is not the same as the amazing platform Twitter used to be, it’s still the Number one social media platform for medicine. I’m happy to be here.

< 3 wks to #ASCO26, here is a📝 of 🔑abstracts for general onc that could guide our SoC! - #RASolute302 - #EPISODE3 - #LIBRETTO432 - #HARMONi6 - #PROTEUS - #EV302 - #SARC041 - #persevERA - #origAMI5 - #MajesTEC9 & #SUCCESOR2 #OncTwitter @ASCO @OncoAlert @OncUpdates

HOPE 💜

YOU MUST LEARN TO ENJOY LIFE WITHOUT NEEDING AN AUDIENCE TO SEE THAT YOU ARE ENJOYING LIFE

Concert tickets and him ⬇️ #JIN

There’s been a lot of news lately about a new therapy, a pill called daraxonrasib, that approximately doubles overall survival in patients with previously treated metastatic #pancreaticcancer as compared with standard intravenous chemotherapy. 💊 These Phase III clinical trial results, announced in April, prompted news coverage and a wave of media attention. Daraxonrasib is a RAS inhibitor, which means it targets mutations found in more than 90% of pancreatic cancer cases and has the potential to greatly expand access to targeted therapies. For patients faced with a pancreatic cancer diagnosis right now, there’s a lot of information to digest as the drug moves into the U.S. Food and Drug Administration approval process. 💜 Our Case Managers are here to help you plan for conversations with your doctor about treatment options, including daraxonrasib through an Expanded Access Program, as well as share personalized educational materials about everything from emerging therapies to support resources and self-advocacy. We can also help you access biomarker testing — a critical step to explore clinical trials and help find the best treatment options available for you today. Read about the latest developments related to daraxonrasib, including more about clinical trial results and the now available Expanded Access Program at 🔗 bit.ly/42d2CAb.